Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019046186) TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/046186 International Application No.: PCT/US2018/048131
Publication Date: 07.03.2019 International Filing Date: 27.08.2018
IPC:
A61K 31/165 (2006.01) ,C07D 209/46 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
16
Amides, e.g. hydroxamic acids
165
having aromatic rings, e.g. colchicine, atenolol, progabide
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
209
Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02
condensed with one carbocyclic ring
44
Iso-indoles; Hydrogenated iso-indoles
46
with an oxygen atom in position 1
Applicants:
ENANTA PHARMACEUTICALS, INC. [US/US]; 500 Arsenal Street Watertown, MA 02472, US
Inventors:
WANG, Guoqiang; US
HE, Jing; US
WANG, Bin; US
SHEN, Ruichao; US
GRANGER, Brett; US
OR, Yat, Sun; US
Agent:
HARLAN, Edgar, W.; US
ELMORE, Carolyn, S.; US
Priority Data:
62/550,95128.08.2017US
Title (EN) TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
(FR) INHIBITEURS DE LA KINASE 1 RÉGULANT LE SIGNAL APOPTOTIQUE CONTENANT DES TÉTRAZOLES ET MÉTHODES D'UTILISATION DE CEUX-CI
Abstract:
(EN) The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: (I) which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
(FR) La présente invention concerne des composés de formule (I), ou des sels, un ester, un stéréoisomère, un tautomère, un solvate, un hydrate pharmaceutiquement acceptables desdits composés ou une combinaison de ceux-ci, lesquels composés inhibent la kinase 1 régulant le signal apoptotique (ASK-1), qui est associée aux troubles auto-immuns, aux troubles neurodégénératifs, aux maladies inflammatoires, aux néphropathies chroniques et aux maladies cardiovasculaires. La présente invention concerne en outre des compositions pharmaceutiques comportant les composés mentionnés ci-dessus, destinées à être administrées à un sujet souffrant d'une maladie liée à ASK-1. L'invention concerne en outre des méthodes de traitement d'une maladie liée à ASK-1 chez un sujet par administration d'une composition pharmaceutique renfermant les composés de la présente invention. La présente invention concerne plus particulièrement des méthodes d'inhibition de la kinase ASK-1 associée à la stéatose hépatique, notamment la stéatose hépatique non alcoolique (NAFLD) et la stéatohépatite non alcoolique (NASH).
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)